Detalhe da pesquisa
1.
Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
Breast Cancer Res Treat
; 203(3): 463-475, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903899
2.
Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy.
J Magn Reson Imaging
; 2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38294179
3.
Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.
CA Cancer J Clin
; 67(3): 194-232, 2017 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28436999
4.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 24(2): 162-174, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36623515
5.
A detailed description of the distress trajectory from pre- to post-treatment in breast cancer patients receiving neoadjuvant chemotherapy.
Breast Cancer Res Treat
; 197(2): 299-305, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36383306
6.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Breast Cancer Res Treat
; 199(3): 457-469, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061619
7.
Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
Ann Surg Oncol
; 30(3): 1663-1668, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094691
8.
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Int J Cancer
; 150(12): 2025-2037, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133007
9.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166679
10.
Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer.
Ann Surg Oncol
; 29(5): 2882-2894, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35000083
11.
Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
J Magn Reson Imaging
; 56(6): 1901-1909, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499264
12.
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations.
Oncology (Williston Park)
; 36(5): 276-287, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576178
13.
Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience.
Int J Cancer
; 148(4): 961-970, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32748402
14.
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Br J Cancer
; 125(5): 679-686, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158598
15.
Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression.
Breast Cancer Res Treat
; 189(2): 333-345, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34241740
16.
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Breast Cancer Res Treat
; 189(2): 455-461, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34131830
17.
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Breast Cancer Res Treat
; 188(1): 179-190, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33641083
18.
Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype.
Br J Cancer
; 123(9): 1417-1423, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32747747
19.
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Oncologist
; 25(6): e909-e919, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32003919
20.
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Oncologist
; 25(2): e214-e222, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043771